Background: Intravitreal ranibizumab and pegaptanib are registered for neovascular age-
related macular degeneration. No formal safety study has been conducted for intravitreal …

Transscleral delivery has emerged as an attractive method for treating retinal disorders
because it offers localized delivery of drugs as a less invasive method compared to …

Nanotherapeutics based on biocompatible lipid matrices allow for enhanced solubility of
poorly soluble compounds in the treatment of ophthalmic diseases, overcoming the …

Objective: To review the efficacy and safety of off-label use of bevacizumab for neovascular
ocular diseases. Data Sources: A PubMed (1966–January 2007) search was conducted …

Purpose: To study retinal pigment epithelium (RPE) tears after off-label intravitreal
bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for neovascular …

Methods: The authors conducted a comprehensive literature search of RPE tears or rips of
any etiology using the PubMed database. They have also included a retrospective analysis …

PURPOSE: To assess the potential effect of intravitreal bevacizumab (IVB)(Avastin;
Genentech, South San Francisco, California, USA) on retinal function and anatomic recovery …

Purpose: The purpose was to study preinjection optical coherence tomography–related
factors in age-related macular degeneration eyes with retinal pigment epithelial detachment …

Purpose: To identify fluorescein angiography and optical coherence tomography (OCT)
predictors for retinal pigment epithelial (RPE) tear in eyes with pigment epithelium …

OBJECTIVE: To examine the evidence about the safety and efficacy of anti–vascular
endothelial growth factor (VEGF) pharmacotherapies for the treatment of neovascular age …